Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
5.04
+0.17 (3.60%)
At close: Aug 24, 2026, 4:00 PM EDT
4.970
-0.070 (-1.29%)
After-hours: Aug 24, 2026, 4:35 PM EDT

Ernexa Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
--0.580.07--
Revenue Growth
--755.88%---
Gross Profit
--0.49-0.17--
Operating Income
-11.74-9.32-17.25-20.68-27.23-27.43
Net Income
-12.27-14.1-44.56-21.68-24.6-122.56
Earnings Per Share
-18.60-55.89-1224.04-1530.17--
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
5.031.881.737.5811.4516.99
Total Debt
0.350.490.6841.841.182.72
Net Cash (Debt)
4.681.391.05-34.2710.2614.26
Net Cash Growth
25.71%33.40%---28.03%-
Net Cash Per Share
7.095.5328.71-2418.18--

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-8.84-7.02-15.84-20.41-20.98-23.49
Capital Expenditures
-0.04-0.04-0.37-0.02-0.3-0.15
Free Cash Flow
-8.88-7.05-16.21-20.43-21.27-23.64
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
--83.50%-247.06%--
Operating Margin
---2963.92%-30404.41%--
Pretax Margin
---7647.59%-31869.12%--
Profit Margin
---7655.50%-31888.23%--
FCF Margin
---2784.36%-30039.71%--

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
--25.95142.81--